Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 73
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 73,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'catslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 73,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/natco-pharma-wins-cancer-drug-case-r-sivaraman-19744/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/natco-pharma-wins-cancer-drug-case-r-sivaraman-19744/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'catslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 73
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Code Context


        trigger_error($message, E_USER_DEPRECATED);

    }
$message = 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 74
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php.'
$stackFrame = (int) 1
$trace = [
	(int) 0 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ServerRequest.php',
		'line' => (int) 2421,
		'function' => 'deprecationWarning',
		'args' => [
			(int) 0 => 'The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead.'
		]
	],
	(int) 1 => [
		'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
		'line' => (int) 74,
		'function' => 'offsetGet',
		'class' => 'Cake\Http\ServerRequest',
		'object' => object(Cake\Http\ServerRequest) {},
		'type' => '->',
		'args' => [
			(int) 0 => 'artileslug'
		]
	],
	(int) 2 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Controller/Controller.php',
		'line' => (int) 610,
		'function' => 'printArticle',
		'class' => 'App\Controller\ArtileDetailController',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 3 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 120,
		'function' => 'invokeAction',
		'class' => 'Cake\Controller\Controller',
		'object' => object(App\Controller\ArtileDetailController) {},
		'type' => '->',
		'args' => []
	],
	(int) 4 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/ActionDispatcher.php',
		'line' => (int) 94,
		'function' => '_invoke',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(App\Controller\ArtileDetailController) {}
		]
	],
	(int) 5 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/BaseApplication.php',
		'line' => (int) 235,
		'function' => 'dispatch',
		'class' => 'Cake\Http\ActionDispatcher',
		'object' => object(Cake\Http\ActionDispatcher) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 6 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Http\BaseApplication',
		'object' => object(App\Application) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 7 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/RoutingMiddleware.php',
		'line' => (int) 162,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 8 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\RoutingMiddleware',
		'object' => object(Cake\Routing\Middleware\RoutingMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 9 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Routing/Middleware/AssetMiddleware.php',
		'line' => (int) 88,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 10 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Routing\Middleware\AssetMiddleware',
		'object' => object(Cake\Routing\Middleware\AssetMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 11 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Middleware/ErrorHandlerMiddleware.php',
		'line' => (int) 96,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 12 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 65,
		'function' => '__invoke',
		'class' => 'Cake\Error\Middleware\ErrorHandlerMiddleware',
		'object' => object(Cake\Error\Middleware\ErrorHandlerMiddleware) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {},
			(int) 2 => object(Cake\Http\Runner) {}
		]
	],
	(int) 13 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Runner.php',
		'line' => (int) 51,
		'function' => '__invoke',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\ServerRequest) {},
			(int) 1 => object(Cake\Http\Response) {}
		]
	],
	(int) 14 => [
		'file' => '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Http/Server.php',
		'line' => (int) 98,
		'function' => 'run',
		'class' => 'Cake\Http\Runner',
		'object' => object(Cake\Http\Runner) {},
		'type' => '->',
		'args' => [
			(int) 0 => object(Cake\Http\MiddlewareQueue) {},
			(int) 1 => object(Cake\Http\ServerRequest) {},
			(int) 2 => object(Cake\Http\Response) {}
		]
	],
	(int) 15 => [
		'file' => '/home/brlfuser/public_html/webroot/index.php',
		'line' => (int) 39,
		'function' => 'run',
		'class' => 'Cake\Http\Server',
		'object' => object(Cake\Http\Server) {},
		'type' => '->',
		'args' => []
	]
]
$frame = [
	'file' => '/home/brlfuser/public_html/src/Controller/ArtileDetailController.php',
	'line' => (int) 74,
	'function' => 'offsetGet',
	'class' => 'Cake\Http\ServerRequest',
	'object' => object(Cake\Http\ServerRequest) {
		trustProxy => false
		[protected] params => [
			[maximum depth reached]
		]
		[protected] data => [[maximum depth reached]]
		[protected] query => [[maximum depth reached]]
		[protected] cookies => [
			[maximum depth reached]
		]
		[protected] _environment => [
			[maximum depth reached]
		]
		[protected] url => 'latest-news-updates/natco-pharma-wins-cancer-drug-case-r-sivaraman-19744/print'
		[protected] base => ''
		[protected] webroot => '/'
		[protected] here => '/latest-news-updates/natco-pharma-wins-cancer-drug-case-r-sivaraman-19744/print'
		[protected] trustedProxies => [[maximum depth reached]]
		[protected] _input => null
		[protected] _detectors => [
			[maximum depth reached]
		]
		[protected] _detectorCache => [
			[maximum depth reached]
		]
		[protected] stream => object(Zend\Diactoros\PhpInputStream) {}
		[protected] uri => object(Zend\Diactoros\Uri) {}
		[protected] session => object(Cake\Http\Session) {}
		[protected] attributes => [[maximum depth reached]]
		[protected] emulatedAttributes => [
			[maximum depth reached]
		]
		[protected] uploadedFiles => [[maximum depth reached]]
		[protected] protocol => null
		[protected] requestTarget => null
		[private] deprecatedProperties => [
			[maximum depth reached]
		]
	},
	'type' => '->',
	'args' => [
		(int) 0 => 'artileslug'
	]
]
deprecationWarning - CORE/src/Core/functions.php, line 311
Cake\Http\ServerRequest::offsetGet() - CORE/src/Http/ServerRequest.php, line 2421
App\Controller\ArtileDetailController::printArticle() - APP/Controller/ArtileDetailController.php, line 74
Cake\Controller\Controller::invokeAction() - CORE/src/Controller/Controller.php, line 610
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 120
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51
Cake\Http\Server::run() - CORE/src/Http/Server.php, line 98

Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Code Context
            if (Configure::read('debug')) {

                trigger_error($message, E_USER_WARNING);

            } else {
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f560e1dffa5-trace').style.display = (document.getElementById('cakeErr67f560e1dffa5-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f560e1dffa5-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f560e1dffa5-code').style.display = (document.getElementById('cakeErr67f560e1dffa5-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f560e1dffa5-context').style.display = (document.getElementById('cakeErr67f560e1dffa5-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f560e1dffa5-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f560e1dffa5-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 19606,
		&#039;title&#039; =&gt; &#039;Natco Pharma wins cancer drug case-R Sivaraman&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;Bayer&#039;s plea dismissed by the Intellectual Property Appellate Board&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a patented cancer drug of multinational pharma major Bayer Corporation. The order will pave the way for reduction in the prices of costly life saving drugs.&lt;br /&gt;
&lt;br /&gt;
Disposing an appeal filed by Bayer Corporation, the Board comprising its Chairman Justice Prabha Sridevan and member D.P.S. Parmar held that various international conventions and Indian laws allowed the member countries to grant such compulsory licence in order to make medicine cheaply available to the public.&lt;br /&gt;
&lt;br /&gt;
Declining to interfere with the order of compulsory licence, the Board said, &amp;ldquo;We are not inclined to interfere with the order of Controller General in the interest of the public. The invention must be available to the public at reasonable and affordable price if not compulsory licence is given.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;We must bear in the mind of public interest but neither the investor nor the compulsory licence applicant. Patents are granted to benefit the inventions to the public.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
As per the licence conditions imposed by Controller, Natco had to pay a six per cent royalty to Bayer from the sales of generic drug Nexavar. Modifying this, the IPAB directed Natco to pay seven percent royalty. The IPAB also imposed Rs.50,000 cost on Natco for some &amp;ldquo;misinformation&amp;rdquo; in its affidavit.&lt;br /&gt;
&lt;br /&gt;
Bayer obtained a patent in India in 2008 for Nexavar which cost Rs. 2.8 lakh for a pack of 120 tablets, equivalent to a month&amp;rsquo;s dosage. On March 9, last year, the Controller of Patents, Mumbai, granted the first-ever compulsory licence to Natco to make &amp;lsquo;sorofenib tosylate&amp;rsquo;, a generic version of Bayer&amp;rsquo;s high-priced anti-cancer drug Nexavar. Natco was told to sell the pack at Rs. 8,800.&lt;br /&gt;
&lt;br /&gt;
Bayer appealed against the Controller&amp;rsquo;s order before the IPAB. Among other reasons, it contended that Cipla had started selling its generic version at a lower price, rendering the compulsory licence unnecessary as the drug was available at a reasonable price.&lt;br /&gt;
&lt;br /&gt;
Pronouncing the order on Monday, Justice Prabha Sridevan dealt elaborately with the appeal.&lt;br /&gt;
&lt;br /&gt;
Upholding the compulsory licence, the IPAB pointed out that even after obtaining patent, Bayer had not made the drug available on a large scale and at an affordable price within the stipulated time.&lt;br /&gt;
&lt;br /&gt;
Going into various submissions and affidavits filed by Bayer, the Board also came to conclusion that its pricing of Rs.2.8 lakh was not affordable.&lt;br /&gt;
&lt;/div&gt;
&lt;div align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/div&gt;
&lt;div align=&quot;justify&quot;&gt;
&lt;em&gt;Reuters reports:&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
In a separate case, Bayer has accused another Indian drugmaker, Cipla, of infringing its patent on Nexavar.&lt;br /&gt;
&lt;br /&gt;
Cipla had launched its generic version of Nexavar before Natco won the compulsory licence. Cipla undercut Natco&amp;rsquo;s price in May last year and now sells the drug at Rs.6,840 for a month&amp;rsquo;s dose.&lt;br /&gt;
&lt;br /&gt;
Among other setbacks for Western drug companies, India has revoked patents granted to Pfizer Inc&amp;rsquo;s cancer drug Sutent, Roche Holding AG&amp;rsquo;s hepatitis C drug Pegasys and Merck &amp;amp; Co&amp;rsquo;s asthma treatment aerosol suspension formulation. Another case involving drug patents is now in front of the Supreme Court, with Novartis battling against an earlier decision refusing it a patent on cancer drug Glivec. &lt;br /&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 4 March, 2013, http://www.thehindu.com/business/companies/natco-pharma-wins-cancer-drug-case/article4475762.ece&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;natco-pharma-wins-cancer-drug-case-r-sivaraman-19744&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 19744,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 19606,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Natco Pharma wins cancer drug case-R Sivaraman&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,patents,Cancer,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu

Bayer&#039;s plea dismissed by the Intellectual Property Appellate Board

The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;br /&gt;&lt;br /&gt;&lt;em&gt;Bayer&#039;s plea dismissed by the Intellectual Property Appellate Board&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a patented cancer drug of multinational pharma major Bayer Corporation. The order will pave the way for reduction in the prices of costly life saving drugs.&lt;br /&gt;&lt;br /&gt;Disposing an appeal filed by Bayer Corporation, the Board comprising its Chairman Justice Prabha Sridevan and member D.P.S. Parmar held that various international conventions and Indian laws allowed the member countries to grant such compulsory licence in order to make medicine cheaply available to the public.&lt;br /&gt;&lt;br /&gt;Declining to interfere with the order of compulsory licence, the Board said, &amp;ldquo;We are not inclined to interfere with the order of Controller General in the interest of the public. The invention must be available to the public at reasonable and affordable price if not compulsory licence is given.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;&amp;ldquo;We must bear in the mind of public interest but neither the investor nor the compulsory licence applicant. Patents are granted to benefit the inventions to the public.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;As per the licence conditions imposed by Controller, Natco had to pay a six per cent royalty to Bayer from the sales of generic drug Nexavar. Modifying this, the IPAB directed Natco to pay seven percent royalty. The IPAB also imposed Rs.50,000 cost on Natco for some &amp;ldquo;misinformation&amp;rdquo; in its affidavit.&lt;br /&gt;&lt;br /&gt;Bayer obtained a patent in India in 2008 for Nexavar which cost Rs. 2.8 lakh for a pack of 120 tablets, equivalent to a month&amp;rsquo;s dosage. On March 9, last year, the Controller of Patents, Mumbai, granted the first-ever compulsory licence to Natco to make &amp;lsquo;sorofenib tosylate&amp;rsquo;, a generic version of Bayer&amp;rsquo;s high-priced anti-cancer drug Nexavar. Natco was told to sell the pack at Rs. 8,800.&lt;br /&gt;&lt;br /&gt;Bayer appealed against the Controller&amp;rsquo;s order before the IPAB. Among other reasons, it contended that Cipla had started selling its generic version at a lower price, rendering the compulsory licence unnecessary as the drug was available at a reasonable price.&lt;br /&gt;&lt;br /&gt;Pronouncing the order on Monday, Justice Prabha Sridevan dealt elaborately with the appeal.&lt;br /&gt;&lt;br /&gt;Upholding the compulsory licence, the IPAB pointed out that even after obtaining patent, Bayer had not made the drug available on a large scale and at an affordable price within the stipulated time.&lt;br /&gt;&lt;br /&gt;Going into various submissions and affidavits filed by Bayer, the Board also came to conclusion that its pricing of Rs.2.8 lakh was not affordable.&lt;br /&gt;&lt;/div&gt;&lt;div align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div align=&quot;justify&quot;&gt;&lt;em&gt;Reuters reports:&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;In a separate case, Bayer has accused another Indian drugmaker, Cipla, of infringing its patent on Nexavar.&lt;br /&gt;&lt;br /&gt;Cipla had launched its generic version of Nexavar before Natco won the compulsory licence. Cipla undercut Natco&amp;rsquo;s price in May last year and now sells the drug at Rs.6,840 for a month&amp;rsquo;s dose.&lt;br /&gt;&lt;br /&gt;Among other setbacks for Western drug companies, India has revoked patents granted to Pfizer Inc&amp;rsquo;s cancer drug Sutent, Roche Holding AG&amp;rsquo;s hepatitis C drug Pegasys and Merck &amp;amp; Co&amp;rsquo;s asthma treatment aerosol suspension formulation. Another case involving drug patents is now in front of the Supreme Court, with Novartis battling against an earlier decision refusing it a patent on cancer drug Glivec. &lt;br /&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 19606,
	&#039;title&#039; =&gt; &#039;Natco Pharma wins cancer drug case-R Sivaraman&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;Bayer&#039;s plea dismissed by the Intellectual Property Appellate Board&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a patented cancer drug of multinational pharma major Bayer Corporation. The order will pave the way for reduction in the prices of costly life saving drugs.&lt;br /&gt;
&lt;br /&gt;
Disposing an appeal filed by Bayer Corporation, the Board comprising its Chairman Justice Prabha Sridevan and member D.P.S. Parmar held that various international conventions and Indian laws allowed the member countries to grant such compulsory licence in order to make medicine cheaply available to the public.&lt;br /&gt;
&lt;br /&gt;
Declining to interfere with the order of compulsory licence, the Board said, &amp;ldquo;We are not inclined to interfere with the order of Controller General in the interest of the public. The invention must be available to the public at reasonable and affordable price if not compulsory licence is given.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;We must bear in the mind of public interest but neither the investor nor the compulsory licence applicant. Patents are granted to benefit the inventions to the public.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
As per the licence conditions imposed by Controller, Natco had to pay a six per cent royalty to Bayer from the sales of generic drug Nexavar. Modifying this, the IPAB directed Natco to pay seven percent royalty. The IPAB also imposed Rs.50,000 cost on Natco for some &amp;ldquo;misinformation&amp;rdquo; in its affidavit.&lt;br /&gt;
&lt;br /&gt;
Bayer obtained a patent in India in 2008 for Nexavar which cost Rs. 2.8 lakh for a pack of 120 tablets, equivalent to a month&amp;rsquo;s dosage. On March 9, last year, the Controller of Patents, Mumbai, granted the first-ever compulsory licence to Natco to make &amp;lsquo;sorofenib tosylate&amp;rsquo;, a generic version of Bayer&amp;rsquo;s high-priced anti-cancer drug Nexavar. Natco was told to sell the pack at Rs. 8,800.&lt;br /&gt;
&lt;br /&gt;
Bayer appealed against the Controller&amp;rsquo;s order before the IPAB. Among other reasons, it contended that Cipla had started selling its generic version at a lower price, rendering the compulsory licence unnecessary as the drug was available at a reasonable price.&lt;br /&gt;
&lt;br /&gt;
Pronouncing the order on Monday, Justice Prabha Sridevan dealt elaborately with the appeal.&lt;br /&gt;
&lt;br /&gt;
Upholding the compulsory licence, the IPAB pointed out that even after obtaining patent, Bayer had not made the drug available on a large scale and at an affordable price within the stipulated time.&lt;br /&gt;
&lt;br /&gt;
Going into various submissions and affidavits filed by Bayer, the Board also came to conclusion that its pricing of Rs.2.8 lakh was not affordable.&lt;br /&gt;
&lt;/div&gt;
&lt;div align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/div&gt;
&lt;div align=&quot;justify&quot;&gt;
&lt;em&gt;Reuters reports:&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
In a separate case, Bayer has accused another Indian drugmaker, Cipla, of infringing its patent on Nexavar.&lt;br /&gt;
&lt;br /&gt;
Cipla had launched its generic version of Nexavar before Natco won the compulsory licence. Cipla undercut Natco&amp;rsquo;s price in May last year and now sells the drug at Rs.6,840 for a month&amp;rsquo;s dose.&lt;br /&gt;
&lt;br /&gt;
Among other setbacks for Western drug companies, India has revoked patents granted to Pfizer Inc&amp;rsquo;s cancer drug Sutent, Roche Holding AG&amp;rsquo;s hepatitis C drug Pegasys and Merck &amp;amp; Co&amp;rsquo;s asthma treatment aerosol suspension formulation. Another case involving drug patents is now in front of the Supreme Court, with Novartis battling against an earlier decision refusing it a patent on cancer drug Glivec. &lt;br /&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 4 March, 2013, http://www.thehindu.com/business/companies/natco-pharma-wins-cancer-drug-case/article4475762.ece&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;natco-pharma-wins-cancer-drug-case-r-sivaraman-19744&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 19744,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 19606
$metaTitle = &#039;LATEST NEWS UPDATES | Natco Pharma wins cancer drug case-R Sivaraman&#039;
$metaKeywords = &#039;medicines,patents,Cancer,Health&#039;
$metaDesc = &#039;
-The Hindu

Bayer&#039;s plea dismissed by the Intellectual Property Appellate Board

The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;br /&gt;&lt;br /&gt;&lt;em&gt;Bayer&#039;s plea dismissed by the Intellectual Property Appellate Board&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a patented cancer drug of multinational pharma major Bayer Corporation. The order will pave the way for reduction in the prices of costly life saving drugs.&lt;br /&gt;&lt;br /&gt;Disposing an appeal filed by Bayer Corporation, the Board comprising its Chairman Justice Prabha Sridevan and member D.P.S. Parmar held that various international conventions and Indian laws allowed the member countries to grant such compulsory licence in order to make medicine cheaply available to the public.&lt;br /&gt;&lt;br /&gt;Declining to interfere with the order of compulsory licence, the Board said, &amp;ldquo;We are not inclined to interfere with the order of Controller General in the interest of the public. The invention must be available to the public at reasonable and affordable price if not compulsory licence is given.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;&amp;ldquo;We must bear in the mind of public interest but neither the investor nor the compulsory licence applicant. Patents are granted to benefit the inventions to the public.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;As per the licence conditions imposed by Controller, Natco had to pay a six per cent royalty to Bayer from the sales of generic drug Nexavar. Modifying this, the IPAB directed Natco to pay seven percent royalty. The IPAB also imposed Rs.50,000 cost on Natco for some &amp;ldquo;misinformation&amp;rdquo; in its affidavit.&lt;br /&gt;&lt;br /&gt;Bayer obtained a patent in India in 2008 for Nexavar which cost Rs. 2.8 lakh for a pack of 120 tablets, equivalent to a month&amp;rsquo;s dosage. On March 9, last year, the Controller of Patents, Mumbai, granted the first-ever compulsory licence to Natco to make &amp;lsquo;sorofenib tosylate&amp;rsquo;, a generic version of Bayer&amp;rsquo;s high-priced anti-cancer drug Nexavar. Natco was told to sell the pack at Rs. 8,800.&lt;br /&gt;&lt;br /&gt;Bayer appealed against the Controller&amp;rsquo;s order before the IPAB. Among other reasons, it contended that Cipla had started selling its generic version at a lower price, rendering the compulsory licence unnecessary as the drug was available at a reasonable price.&lt;br /&gt;&lt;br /&gt;Pronouncing the order on Monday, Justice Prabha Sridevan dealt elaborately with the appeal.&lt;br /&gt;&lt;br /&gt;Upholding the compulsory licence, the IPAB pointed out that even after obtaining patent, Bayer had not made the drug available on a large scale and at an affordable price within the stipulated time.&lt;br /&gt;&lt;br /&gt;Going into various submissions and affidavits filed by Bayer, the Board also came to conclusion that its pricing of Rs.2.8 lakh was not affordable.&lt;br /&gt;&lt;/div&gt;&lt;div align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div align=&quot;justify&quot;&gt;&lt;em&gt;Reuters reports:&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;In a separate case, Bayer has accused another Indian drugmaker, Cipla, of infringing its patent on Nexavar.&lt;br /&gt;&lt;br /&gt;Cipla had launched its generic version of Nexavar before Natco won the compulsory licence. Cipla undercut Natco&amp;rsquo;s price in May last year and now sells the drug at Rs.6,840 for a month&amp;rsquo;s dose.&lt;br /&gt;&lt;br /&gt;Among other setbacks for Western drug companies, India has revoked patents granted to Pfizer Inc&amp;rsquo;s cancer drug Sutent, Roche Holding AG&amp;rsquo;s hepatitis C drug Pegasys and Merck &amp;amp; Co&amp;rsquo;s asthma treatment aerosol suspension formulation. Another case involving drug patents is now in front of the Supreme Court, with Novartis battling against an earlier decision refusing it a patent on cancer drug Glivec. &lt;br /&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/natco-pharma-wins-cancer-drug-case-r-sivaraman-19744.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Natco Pharma wins cancer drug case-R Sivaraman | Im4change.org</title>
    <meta name="description" content="
-The Hindu

Bayer's plea dismissed by the Intellectual Property Appellate Board

The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Natco Pharma wins cancer drug case-R Sivaraman</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu<br /><br /><em>Bayer's plea dismissed by the Intellectual Property Appellate Board<br /></em><br />The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a patented cancer drug of multinational pharma major Bayer Corporation. The order will pave the way for reduction in the prices of costly life saving drugs.<br /><br />Disposing an appeal filed by Bayer Corporation, the Board comprising its Chairman Justice Prabha Sridevan and member D.P.S. Parmar held that various international conventions and Indian laws allowed the member countries to grant such compulsory licence in order to make medicine cheaply available to the public.<br /><br />Declining to interfere with the order of compulsory licence, the Board said, &ldquo;We are not inclined to interfere with the order of Controller General in the interest of the public. The invention must be available to the public at reasonable and affordable price if not compulsory licence is given.&rdquo;<br /><br />&ldquo;We must bear in the mind of public interest but neither the investor nor the compulsory licence applicant. Patents are granted to benefit the inventions to the public.&rdquo;<br /><br />As per the licence conditions imposed by Controller, Natco had to pay a six per cent royalty to Bayer from the sales of generic drug Nexavar. Modifying this, the IPAB directed Natco to pay seven percent royalty. The IPAB also imposed Rs.50,000 cost on Natco for some &ldquo;misinformation&rdquo; in its affidavit.<br /><br />Bayer obtained a patent in India in 2008 for Nexavar which cost Rs. 2.8 lakh for a pack of 120 tablets, equivalent to a month&rsquo;s dosage. On March 9, last year, the Controller of Patents, Mumbai, granted the first-ever compulsory licence to Natco to make &lsquo;sorofenib tosylate&rsquo;, a generic version of Bayer&rsquo;s high-priced anti-cancer drug Nexavar. Natco was told to sell the pack at Rs. 8,800.<br /><br />Bayer appealed against the Controller&rsquo;s order before the IPAB. Among other reasons, it contended that Cipla had started selling its generic version at a lower price, rendering the compulsory licence unnecessary as the drug was available at a reasonable price.<br /><br />Pronouncing the order on Monday, Justice Prabha Sridevan dealt elaborately with the appeal.<br /><br />Upholding the compulsory licence, the IPAB pointed out that even after obtaining patent, Bayer had not made the drug available on a large scale and at an affordable price within the stipulated time.<br /><br />Going into various submissions and affidavits filed by Bayer, the Board also came to conclusion that its pricing of Rs.2.8 lakh was not affordable.<br /></div><div align="justify">&nbsp;</div><div align="justify"><em>Reuters reports:<br /></em><br />In a separate case, Bayer has accused another Indian drugmaker, Cipla, of infringing its patent on Nexavar.<br /><br />Cipla had launched its generic version of Nexavar before Natco won the compulsory licence. Cipla undercut Natco&rsquo;s price in May last year and now sells the drug at Rs.6,840 for a month&rsquo;s dose.<br /><br />Among other setbacks for Western drug companies, India has revoked patents granted to Pfizer Inc&rsquo;s cancer drug Sutent, Roche Holding AG&rsquo;s hepatitis C drug Pegasys and Merck &amp; Co&rsquo;s asthma treatment aerosol suspension formulation. Another case involving drug patents is now in front of the Supreme Court, with Novartis battling against an earlier decision refusing it a patent on cancer drug Glivec. <br /></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$maxBufferLength = (int) 8192
$file = '/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php'
$line = (int) 853
$message = 'Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853'
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 48
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Code Context
            $response->getStatusCode(),

            ($reasonPhrase ? ' ' . $reasonPhrase : '')

        ));
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f560e1dffa5-trace').style.display = (document.getElementById('cakeErr67f560e1dffa5-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f560e1dffa5-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f560e1dffa5-code').style.display = (document.getElementById('cakeErr67f560e1dffa5-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f560e1dffa5-context').style.display = (document.getElementById('cakeErr67f560e1dffa5-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f560e1dffa5-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f560e1dffa5-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 19606,
		&#039;title&#039; =&gt; &#039;Natco Pharma wins cancer drug case-R Sivaraman&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;Bayer&#039;s plea dismissed by the Intellectual Property Appellate Board&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a patented cancer drug of multinational pharma major Bayer Corporation. The order will pave the way for reduction in the prices of costly life saving drugs.&lt;br /&gt;
&lt;br /&gt;
Disposing an appeal filed by Bayer Corporation, the Board comprising its Chairman Justice Prabha Sridevan and member D.P.S. Parmar held that various international conventions and Indian laws allowed the member countries to grant such compulsory licence in order to make medicine cheaply available to the public.&lt;br /&gt;
&lt;br /&gt;
Declining to interfere with the order of compulsory licence, the Board said, &amp;ldquo;We are not inclined to interfere with the order of Controller General in the interest of the public. The invention must be available to the public at reasonable and affordable price if not compulsory licence is given.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;We must bear in the mind of public interest but neither the investor nor the compulsory licence applicant. Patents are granted to benefit the inventions to the public.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
As per the licence conditions imposed by Controller, Natco had to pay a six per cent royalty to Bayer from the sales of generic drug Nexavar. Modifying this, the IPAB directed Natco to pay seven percent royalty. The IPAB also imposed Rs.50,000 cost on Natco for some &amp;ldquo;misinformation&amp;rdquo; in its affidavit.&lt;br /&gt;
&lt;br /&gt;
Bayer obtained a patent in India in 2008 for Nexavar which cost Rs. 2.8 lakh for a pack of 120 tablets, equivalent to a month&amp;rsquo;s dosage. On March 9, last year, the Controller of Patents, Mumbai, granted the first-ever compulsory licence to Natco to make &amp;lsquo;sorofenib tosylate&amp;rsquo;, a generic version of Bayer&amp;rsquo;s high-priced anti-cancer drug Nexavar. Natco was told to sell the pack at Rs. 8,800.&lt;br /&gt;
&lt;br /&gt;
Bayer appealed against the Controller&amp;rsquo;s order before the IPAB. Among other reasons, it contended that Cipla had started selling its generic version at a lower price, rendering the compulsory licence unnecessary as the drug was available at a reasonable price.&lt;br /&gt;
&lt;br /&gt;
Pronouncing the order on Monday, Justice Prabha Sridevan dealt elaborately with the appeal.&lt;br /&gt;
&lt;br /&gt;
Upholding the compulsory licence, the IPAB pointed out that even after obtaining patent, Bayer had not made the drug available on a large scale and at an affordable price within the stipulated time.&lt;br /&gt;
&lt;br /&gt;
Going into various submissions and affidavits filed by Bayer, the Board also came to conclusion that its pricing of Rs.2.8 lakh was not affordable.&lt;br /&gt;
&lt;/div&gt;
&lt;div align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/div&gt;
&lt;div align=&quot;justify&quot;&gt;
&lt;em&gt;Reuters reports:&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
In a separate case, Bayer has accused another Indian drugmaker, Cipla, of infringing its patent on Nexavar.&lt;br /&gt;
&lt;br /&gt;
Cipla had launched its generic version of Nexavar before Natco won the compulsory licence. Cipla undercut Natco&amp;rsquo;s price in May last year and now sells the drug at Rs.6,840 for a month&amp;rsquo;s dose.&lt;br /&gt;
&lt;br /&gt;
Among other setbacks for Western drug companies, India has revoked patents granted to Pfizer Inc&amp;rsquo;s cancer drug Sutent, Roche Holding AG&amp;rsquo;s hepatitis C drug Pegasys and Merck &amp;amp; Co&amp;rsquo;s asthma treatment aerosol suspension formulation. Another case involving drug patents is now in front of the Supreme Court, with Novartis battling against an earlier decision refusing it a patent on cancer drug Glivec. &lt;br /&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 4 March, 2013, http://www.thehindu.com/business/companies/natco-pharma-wins-cancer-drug-case/article4475762.ece&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;natco-pharma-wins-cancer-drug-case-r-sivaraman-19744&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 19744,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 19606,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Natco Pharma wins cancer drug case-R Sivaraman&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,patents,Cancer,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu

Bayer&#039;s plea dismissed by the Intellectual Property Appellate Board

The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;br /&gt;&lt;br /&gt;&lt;em&gt;Bayer&#039;s plea dismissed by the Intellectual Property Appellate Board&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a patented cancer drug of multinational pharma major Bayer Corporation. The order will pave the way for reduction in the prices of costly life saving drugs.&lt;br /&gt;&lt;br /&gt;Disposing an appeal filed by Bayer Corporation, the Board comprising its Chairman Justice Prabha Sridevan and member D.P.S. Parmar held that various international conventions and Indian laws allowed the member countries to grant such compulsory licence in order to make medicine cheaply available to the public.&lt;br /&gt;&lt;br /&gt;Declining to interfere with the order of compulsory licence, the Board said, &amp;ldquo;We are not inclined to interfere with the order of Controller General in the interest of the public. The invention must be available to the public at reasonable and affordable price if not compulsory licence is given.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;&amp;ldquo;We must bear in the mind of public interest but neither the investor nor the compulsory licence applicant. Patents are granted to benefit the inventions to the public.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;As per the licence conditions imposed by Controller, Natco had to pay a six per cent royalty to Bayer from the sales of generic drug Nexavar. Modifying this, the IPAB directed Natco to pay seven percent royalty. The IPAB also imposed Rs.50,000 cost on Natco for some &amp;ldquo;misinformation&amp;rdquo; in its affidavit.&lt;br /&gt;&lt;br /&gt;Bayer obtained a patent in India in 2008 for Nexavar which cost Rs. 2.8 lakh for a pack of 120 tablets, equivalent to a month&amp;rsquo;s dosage. On March 9, last year, the Controller of Patents, Mumbai, granted the first-ever compulsory licence to Natco to make &amp;lsquo;sorofenib tosylate&amp;rsquo;, a generic version of Bayer&amp;rsquo;s high-priced anti-cancer drug Nexavar. Natco was told to sell the pack at Rs. 8,800.&lt;br /&gt;&lt;br /&gt;Bayer appealed against the Controller&amp;rsquo;s order before the IPAB. Among other reasons, it contended that Cipla had started selling its generic version at a lower price, rendering the compulsory licence unnecessary as the drug was available at a reasonable price.&lt;br /&gt;&lt;br /&gt;Pronouncing the order on Monday, Justice Prabha Sridevan dealt elaborately with the appeal.&lt;br /&gt;&lt;br /&gt;Upholding the compulsory licence, the IPAB pointed out that even after obtaining patent, Bayer had not made the drug available on a large scale and at an affordable price within the stipulated time.&lt;br /&gt;&lt;br /&gt;Going into various submissions and affidavits filed by Bayer, the Board also came to conclusion that its pricing of Rs.2.8 lakh was not affordable.&lt;br /&gt;&lt;/div&gt;&lt;div align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div align=&quot;justify&quot;&gt;&lt;em&gt;Reuters reports:&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;In a separate case, Bayer has accused another Indian drugmaker, Cipla, of infringing its patent on Nexavar.&lt;br /&gt;&lt;br /&gt;Cipla had launched its generic version of Nexavar before Natco won the compulsory licence. Cipla undercut Natco&amp;rsquo;s price in May last year and now sells the drug at Rs.6,840 for a month&amp;rsquo;s dose.&lt;br /&gt;&lt;br /&gt;Among other setbacks for Western drug companies, India has revoked patents granted to Pfizer Inc&amp;rsquo;s cancer drug Sutent, Roche Holding AG&amp;rsquo;s hepatitis C drug Pegasys and Merck &amp;amp; Co&amp;rsquo;s asthma treatment aerosol suspension formulation. Another case involving drug patents is now in front of the Supreme Court, with Novartis battling against an earlier decision refusing it a patent on cancer drug Glivec. &lt;br /&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 19606,
	&#039;title&#039; =&gt; &#039;Natco Pharma wins cancer drug case-R Sivaraman&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;Bayer&#039;s plea dismissed by the Intellectual Property Appellate Board&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a patented cancer drug of multinational pharma major Bayer Corporation. The order will pave the way for reduction in the prices of costly life saving drugs.&lt;br /&gt;
&lt;br /&gt;
Disposing an appeal filed by Bayer Corporation, the Board comprising its Chairman Justice Prabha Sridevan and member D.P.S. Parmar held that various international conventions and Indian laws allowed the member countries to grant such compulsory licence in order to make medicine cheaply available to the public.&lt;br /&gt;
&lt;br /&gt;
Declining to interfere with the order of compulsory licence, the Board said, &amp;ldquo;We are not inclined to interfere with the order of Controller General in the interest of the public. The invention must be available to the public at reasonable and affordable price if not compulsory licence is given.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;We must bear in the mind of public interest but neither the investor nor the compulsory licence applicant. Patents are granted to benefit the inventions to the public.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
As per the licence conditions imposed by Controller, Natco had to pay a six per cent royalty to Bayer from the sales of generic drug Nexavar. Modifying this, the IPAB directed Natco to pay seven percent royalty. The IPAB also imposed Rs.50,000 cost on Natco for some &amp;ldquo;misinformation&amp;rdquo; in its affidavit.&lt;br /&gt;
&lt;br /&gt;
Bayer obtained a patent in India in 2008 for Nexavar which cost Rs. 2.8 lakh for a pack of 120 tablets, equivalent to a month&amp;rsquo;s dosage. On March 9, last year, the Controller of Patents, Mumbai, granted the first-ever compulsory licence to Natco to make &amp;lsquo;sorofenib tosylate&amp;rsquo;, a generic version of Bayer&amp;rsquo;s high-priced anti-cancer drug Nexavar. Natco was told to sell the pack at Rs. 8,800.&lt;br /&gt;
&lt;br /&gt;
Bayer appealed against the Controller&amp;rsquo;s order before the IPAB. Among other reasons, it contended that Cipla had started selling its generic version at a lower price, rendering the compulsory licence unnecessary as the drug was available at a reasonable price.&lt;br /&gt;
&lt;br /&gt;
Pronouncing the order on Monday, Justice Prabha Sridevan dealt elaborately with the appeal.&lt;br /&gt;
&lt;br /&gt;
Upholding the compulsory licence, the IPAB pointed out that even after obtaining patent, Bayer had not made the drug available on a large scale and at an affordable price within the stipulated time.&lt;br /&gt;
&lt;br /&gt;
Going into various submissions and affidavits filed by Bayer, the Board also came to conclusion that its pricing of Rs.2.8 lakh was not affordable.&lt;br /&gt;
&lt;/div&gt;
&lt;div align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/div&gt;
&lt;div align=&quot;justify&quot;&gt;
&lt;em&gt;Reuters reports:&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
In a separate case, Bayer has accused another Indian drugmaker, Cipla, of infringing its patent on Nexavar.&lt;br /&gt;
&lt;br /&gt;
Cipla had launched its generic version of Nexavar before Natco won the compulsory licence. Cipla undercut Natco&amp;rsquo;s price in May last year and now sells the drug at Rs.6,840 for a month&amp;rsquo;s dose.&lt;br /&gt;
&lt;br /&gt;
Among other setbacks for Western drug companies, India has revoked patents granted to Pfizer Inc&amp;rsquo;s cancer drug Sutent, Roche Holding AG&amp;rsquo;s hepatitis C drug Pegasys and Merck &amp;amp; Co&amp;rsquo;s asthma treatment aerosol suspension formulation. Another case involving drug patents is now in front of the Supreme Court, with Novartis battling against an earlier decision refusing it a patent on cancer drug Glivec. &lt;br /&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 4 March, 2013, http://www.thehindu.com/business/companies/natco-pharma-wins-cancer-drug-case/article4475762.ece&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;natco-pharma-wins-cancer-drug-case-r-sivaraman-19744&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 19744,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 19606
$metaTitle = &#039;LATEST NEWS UPDATES | Natco Pharma wins cancer drug case-R Sivaraman&#039;
$metaKeywords = &#039;medicines,patents,Cancer,Health&#039;
$metaDesc = &#039;
-The Hindu

Bayer&#039;s plea dismissed by the Intellectual Property Appellate Board

The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;br /&gt;&lt;br /&gt;&lt;em&gt;Bayer&#039;s plea dismissed by the Intellectual Property Appellate Board&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a patented cancer drug of multinational pharma major Bayer Corporation. The order will pave the way for reduction in the prices of costly life saving drugs.&lt;br /&gt;&lt;br /&gt;Disposing an appeal filed by Bayer Corporation, the Board comprising its Chairman Justice Prabha Sridevan and member D.P.S. Parmar held that various international conventions and Indian laws allowed the member countries to grant such compulsory licence in order to make medicine cheaply available to the public.&lt;br /&gt;&lt;br /&gt;Declining to interfere with the order of compulsory licence, the Board said, &amp;ldquo;We are not inclined to interfere with the order of Controller General in the interest of the public. The invention must be available to the public at reasonable and affordable price if not compulsory licence is given.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;&amp;ldquo;We must bear in the mind of public interest but neither the investor nor the compulsory licence applicant. Patents are granted to benefit the inventions to the public.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;As per the licence conditions imposed by Controller, Natco had to pay a six per cent royalty to Bayer from the sales of generic drug Nexavar. Modifying this, the IPAB directed Natco to pay seven percent royalty. The IPAB also imposed Rs.50,000 cost on Natco for some &amp;ldquo;misinformation&amp;rdquo; in its affidavit.&lt;br /&gt;&lt;br /&gt;Bayer obtained a patent in India in 2008 for Nexavar which cost Rs. 2.8 lakh for a pack of 120 tablets, equivalent to a month&amp;rsquo;s dosage. On March 9, last year, the Controller of Patents, Mumbai, granted the first-ever compulsory licence to Natco to make &amp;lsquo;sorofenib tosylate&amp;rsquo;, a generic version of Bayer&amp;rsquo;s high-priced anti-cancer drug Nexavar. Natco was told to sell the pack at Rs. 8,800.&lt;br /&gt;&lt;br /&gt;Bayer appealed against the Controller&amp;rsquo;s order before the IPAB. Among other reasons, it contended that Cipla had started selling its generic version at a lower price, rendering the compulsory licence unnecessary as the drug was available at a reasonable price.&lt;br /&gt;&lt;br /&gt;Pronouncing the order on Monday, Justice Prabha Sridevan dealt elaborately with the appeal.&lt;br /&gt;&lt;br /&gt;Upholding the compulsory licence, the IPAB pointed out that even after obtaining patent, Bayer had not made the drug available on a large scale and at an affordable price within the stipulated time.&lt;br /&gt;&lt;br /&gt;Going into various submissions and affidavits filed by Bayer, the Board also came to conclusion that its pricing of Rs.2.8 lakh was not affordable.&lt;br /&gt;&lt;/div&gt;&lt;div align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div align=&quot;justify&quot;&gt;&lt;em&gt;Reuters reports:&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;In a separate case, Bayer has accused another Indian drugmaker, Cipla, of infringing its patent on Nexavar.&lt;br /&gt;&lt;br /&gt;Cipla had launched its generic version of Nexavar before Natco won the compulsory licence. Cipla undercut Natco&amp;rsquo;s price in May last year and now sells the drug at Rs.6,840 for a month&amp;rsquo;s dose.&lt;br /&gt;&lt;br /&gt;Among other setbacks for Western drug companies, India has revoked patents granted to Pfizer Inc&amp;rsquo;s cancer drug Sutent, Roche Holding AG&amp;rsquo;s hepatitis C drug Pegasys and Merck &amp;amp; Co&amp;rsquo;s asthma treatment aerosol suspension formulation. Another case involving drug patents is now in front of the Supreme Court, with Novartis battling against an earlier decision refusing it a patent on cancer drug Glivec. &lt;br /&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/natco-pharma-wins-cancer-drug-case-r-sivaraman-19744.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Natco Pharma wins cancer drug case-R Sivaraman | Im4change.org</title>
    <meta name="description" content="
-The Hindu

Bayer's plea dismissed by the Intellectual Property Appellate Board

The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Natco Pharma wins cancer drug case-R Sivaraman</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu<br /><br /><em>Bayer's plea dismissed by the Intellectual Property Appellate Board<br /></em><br />The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a patented cancer drug of multinational pharma major Bayer Corporation. The order will pave the way for reduction in the prices of costly life saving drugs.<br /><br />Disposing an appeal filed by Bayer Corporation, the Board comprising its Chairman Justice Prabha Sridevan and member D.P.S. Parmar held that various international conventions and Indian laws allowed the member countries to grant such compulsory licence in order to make medicine cheaply available to the public.<br /><br />Declining to interfere with the order of compulsory licence, the Board said, &ldquo;We are not inclined to interfere with the order of Controller General in the interest of the public. The invention must be available to the public at reasonable and affordable price if not compulsory licence is given.&rdquo;<br /><br />&ldquo;We must bear in the mind of public interest but neither the investor nor the compulsory licence applicant. Patents are granted to benefit the inventions to the public.&rdquo;<br /><br />As per the licence conditions imposed by Controller, Natco had to pay a six per cent royalty to Bayer from the sales of generic drug Nexavar. Modifying this, the IPAB directed Natco to pay seven percent royalty. The IPAB also imposed Rs.50,000 cost on Natco for some &ldquo;misinformation&rdquo; in its affidavit.<br /><br />Bayer obtained a patent in India in 2008 for Nexavar which cost Rs. 2.8 lakh for a pack of 120 tablets, equivalent to a month&rsquo;s dosage. On March 9, last year, the Controller of Patents, Mumbai, granted the first-ever compulsory licence to Natco to make &lsquo;sorofenib tosylate&rsquo;, a generic version of Bayer&rsquo;s high-priced anti-cancer drug Nexavar. Natco was told to sell the pack at Rs. 8,800.<br /><br />Bayer appealed against the Controller&rsquo;s order before the IPAB. Among other reasons, it contended that Cipla had started selling its generic version at a lower price, rendering the compulsory licence unnecessary as the drug was available at a reasonable price.<br /><br />Pronouncing the order on Monday, Justice Prabha Sridevan dealt elaborately with the appeal.<br /><br />Upholding the compulsory licence, the IPAB pointed out that even after obtaining patent, Bayer had not made the drug available on a large scale and at an affordable price within the stipulated time.<br /><br />Going into various submissions and affidavits filed by Bayer, the Board also came to conclusion that its pricing of Rs.2.8 lakh was not affordable.<br /></div><div align="justify">&nbsp;</div><div align="justify"><em>Reuters reports:<br /></em><br />In a separate case, Bayer has accused another Indian drugmaker, Cipla, of infringing its patent on Nexavar.<br /><br />Cipla had launched its generic version of Nexavar before Natco won the compulsory licence. Cipla undercut Natco&rsquo;s price in May last year and now sells the drug at Rs.6,840 for a month&rsquo;s dose.<br /><br />Among other setbacks for Western drug companies, India has revoked patents granted to Pfizer Inc&rsquo;s cancer drug Sutent, Roche Holding AG&rsquo;s hepatitis C drug Pegasys and Merck &amp; Co&rsquo;s asthma treatment aerosol suspension formulation. Another case involving drug patents is now in front of the Supreme Court, with Novartis battling against an earlier decision refusing it a patent on cancer drug Glivec. <br /></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$reasonPhrase = 'OK'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitStatusLine() - CORE/src/Http/ResponseEmitter.php, line 148
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 54
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
Code Context
                    $value

                ), $first);

                $first = false;
$response = object(Cake\Http\Response) {

	'status' => (int) 200,
	'contentType' => 'text/html',
	'headers' => [
		'Content-Type' => [
			[maximum depth reached]
		]
	],
	'file' => null,
	'fileRange' => [],
	'cookies' => object(Cake\Http\Cookie\CookieCollection) {},
	'cacheDirectives' => [],
	'body' => '<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN"
        "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
    <link rel="canonical" href="https://im4change.in/<pre class="cake-error"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f560e1dffa5-trace').style.display = (document.getElementById('cakeErr67f560e1dffa5-trace').style.display == 'none' ? '' : 'none');"><b>Notice</b> (8)</a>: Undefined variable: urlPrefix [<b>APP/Template/Layout/printlayout.ctp</b>, line <b>8</b>]<div id="cakeErr67f560e1dffa5-trace" class="cake-stack-trace" style="display: none;"><a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f560e1dffa5-code').style.display = (document.getElementById('cakeErr67f560e1dffa5-code').style.display == 'none' ? '' : 'none')">Code</a> <a href="javascript:void(0);" onclick="document.getElementById('cakeErr67f560e1dffa5-context').style.display = (document.getElementById('cakeErr67f560e1dffa5-context').style.display == 'none' ? '' : 'none')">Context</a><pre id="cakeErr67f560e1dffa5-code" class="cake-code-dump" style="display: none;"><code><span style="color: #000000"><span style="color: #0000BB"></span><span style="color: #007700">&lt;</span><span style="color: #0000BB">head</span><span style="color: #007700">&gt;
</span></span></code>
<span class="code-highlight"><code><span style="color: #000000">&nbsp;&nbsp;&nbsp;&nbsp;&lt;link&nbsp;rel="canonical"&nbsp;href="<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">Configure</span><span style="color: #007700">::</span><span style="color: #0000BB">read</span><span style="color: #007700">(</span><span style="color: #DD0000">'SITE_URL'</span><span style="color: #007700">);&nbsp;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$urlPrefix</span><span style="color: #007700">;</span><span style="color: #0000BB">?&gt;&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">category</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">slug</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>/<span style="color: #0000BB">&lt;?php&nbsp;</span><span style="color: #007700">echo&nbsp;</span><span style="color: #0000BB">$article_current</span><span style="color: #007700">-&gt;</span><span style="color: #0000BB">seo_url</span><span style="color: #007700">;&nbsp;</span><span style="color: #0000BB">?&gt;</span>.html"/&gt;
</span></code></span>
<code><span style="color: #000000"><span style="color: #0000BB">&nbsp;&nbsp;&nbsp;&nbsp;</span><span style="color: #007700">&lt;</span><span style="color: #0000BB">meta&nbsp;http</span><span style="color: #007700">-</span><span style="color: #0000BB">equiv</span><span style="color: #007700">=</span><span style="color: #DD0000">"Content-Type"&nbsp;</span><span style="color: #0000BB">content</span><span style="color: #007700">=</span><span style="color: #DD0000">"text/html;&nbsp;charset=utf-8"</span><span style="color: #007700">/&gt;
</span></span></code></pre><pre id="cakeErr67f560e1dffa5-context" class="cake-context" style="display: none;">$viewFile = &#039;/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp&#039;
$dataForView = [
	&#039;article_current&#039; =&gt; object(App\Model\Entity\Article) {

		&#039;id&#039; =&gt; (int) 19606,
		&#039;title&#039; =&gt; &#039;Natco Pharma wins cancer drug case-R Sivaraman&#039;,
		&#039;subheading&#039; =&gt; &#039;&#039;,
		&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;Bayer&#039;s plea dismissed by the Intellectual Property Appellate Board&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a patented cancer drug of multinational pharma major Bayer Corporation. The order will pave the way for reduction in the prices of costly life saving drugs.&lt;br /&gt;
&lt;br /&gt;
Disposing an appeal filed by Bayer Corporation, the Board comprising its Chairman Justice Prabha Sridevan and member D.P.S. Parmar held that various international conventions and Indian laws allowed the member countries to grant such compulsory licence in order to make medicine cheaply available to the public.&lt;br /&gt;
&lt;br /&gt;
Declining to interfere with the order of compulsory licence, the Board said, &amp;ldquo;We are not inclined to interfere with the order of Controller General in the interest of the public. The invention must be available to the public at reasonable and affordable price if not compulsory licence is given.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;We must bear in the mind of public interest but neither the investor nor the compulsory licence applicant. Patents are granted to benefit the inventions to the public.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
As per the licence conditions imposed by Controller, Natco had to pay a six per cent royalty to Bayer from the sales of generic drug Nexavar. Modifying this, the IPAB directed Natco to pay seven percent royalty. The IPAB also imposed Rs.50,000 cost on Natco for some &amp;ldquo;misinformation&amp;rdquo; in its affidavit.&lt;br /&gt;
&lt;br /&gt;
Bayer obtained a patent in India in 2008 for Nexavar which cost Rs. 2.8 lakh for a pack of 120 tablets, equivalent to a month&amp;rsquo;s dosage. On March 9, last year, the Controller of Patents, Mumbai, granted the first-ever compulsory licence to Natco to make &amp;lsquo;sorofenib tosylate&amp;rsquo;, a generic version of Bayer&amp;rsquo;s high-priced anti-cancer drug Nexavar. Natco was told to sell the pack at Rs. 8,800.&lt;br /&gt;
&lt;br /&gt;
Bayer appealed against the Controller&amp;rsquo;s order before the IPAB. Among other reasons, it contended that Cipla had started selling its generic version at a lower price, rendering the compulsory licence unnecessary as the drug was available at a reasonable price.&lt;br /&gt;
&lt;br /&gt;
Pronouncing the order on Monday, Justice Prabha Sridevan dealt elaborately with the appeal.&lt;br /&gt;
&lt;br /&gt;
Upholding the compulsory licence, the IPAB pointed out that even after obtaining patent, Bayer had not made the drug available on a large scale and at an affordable price within the stipulated time.&lt;br /&gt;
&lt;br /&gt;
Going into various submissions and affidavits filed by Bayer, the Board also came to conclusion that its pricing of Rs.2.8 lakh was not affordable.&lt;br /&gt;
&lt;/div&gt;
&lt;div align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/div&gt;
&lt;div align=&quot;justify&quot;&gt;
&lt;em&gt;Reuters reports:&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
In a separate case, Bayer has accused another Indian drugmaker, Cipla, of infringing its patent on Nexavar.&lt;br /&gt;
&lt;br /&gt;
Cipla had launched its generic version of Nexavar before Natco won the compulsory licence. Cipla undercut Natco&amp;rsquo;s price in May last year and now sells the drug at Rs.6,840 for a month&amp;rsquo;s dose.&lt;br /&gt;
&lt;br /&gt;
Among other setbacks for Western drug companies, India has revoked patents granted to Pfizer Inc&amp;rsquo;s cancer drug Sutent, Roche Holding AG&amp;rsquo;s hepatitis C drug Pegasys and Merck &amp;amp; Co&amp;rsquo;s asthma treatment aerosol suspension formulation. Another case involving drug patents is now in front of the Supreme Court, with Novartis battling against an earlier decision refusing it a patent on cancer drug Glivec. &lt;br /&gt;
&lt;/div&gt;&#039;,
		&#039;credit_writer&#039; =&gt; &#039;The Hindu, 4 March, 2013, http://www.thehindu.com/business/companies/natco-pharma-wins-cancer-drug-case/article4475762.ece&#039;,
		&#039;article_img&#039; =&gt; &#039;&#039;,
		&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
		&#039;status&#039; =&gt; (int) 1,
		&#039;show_on_home&#039; =&gt; (int) 1,
		&#039;lang&#039; =&gt; &#039;EN&#039;,
		&#039;category_id&#039; =&gt; (int) 16,
		&#039;tag_keyword&#039; =&gt; &#039;&#039;,
		&#039;seo_url&#039; =&gt; &#039;natco-pharma-wins-cancer-drug-case-r-sivaraman-19744&#039;,
		&#039;meta_title&#039; =&gt; null,
		&#039;meta_keywords&#039; =&gt; null,
		&#039;meta_description&#039; =&gt; null,
		&#039;noindex&#039; =&gt; (int) 0,
		&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
		&#039;most_visit_section_id&#039; =&gt; null,
		&#039;article_big_img&#039; =&gt; null,
		&#039;liveid&#039; =&gt; (int) 19744,
		&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
		&#039;edate&#039; =&gt; &#039;&#039;,
		&#039;tags&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
		&#039;[new]&#039; =&gt; false,
		&#039;[accessible]&#039; =&gt; [
			[maximum depth reached]
		],
		&#039;[dirty]&#039; =&gt; [[maximum depth reached]],
		&#039;[original]&#039; =&gt; [[maximum depth reached]],
		&#039;[virtual]&#039; =&gt; [[maximum depth reached]],
		&#039;[hasErrors]&#039; =&gt; false,
		&#039;[errors]&#039; =&gt; [[maximum depth reached]],
		&#039;[invalid]&#039; =&gt; [[maximum depth reached]],
		&#039;[repository]&#039; =&gt; &#039;Articles&#039;
	
	},
	&#039;articleid&#039; =&gt; (int) 19606,
	&#039;metaTitle&#039; =&gt; &#039;LATEST NEWS UPDATES | Natco Pharma wins cancer drug case-R Sivaraman&#039;,
	&#039;metaKeywords&#039; =&gt; &#039;medicines,patents,Cancer,Health&#039;,
	&#039;metaDesc&#039; =&gt; &#039;
-The Hindu

Bayer&#039;s plea dismissed by the Intellectual Property Appellate Board

The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a...&#039;,
	&#039;disp&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;br /&gt;&lt;br /&gt;&lt;em&gt;Bayer&#039;s plea dismissed by the Intellectual Property Appellate Board&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a patented cancer drug of multinational pharma major Bayer Corporation. The order will pave the way for reduction in the prices of costly life saving drugs.&lt;br /&gt;&lt;br /&gt;Disposing an appeal filed by Bayer Corporation, the Board comprising its Chairman Justice Prabha Sridevan and member D.P.S. Parmar held that various international conventions and Indian laws allowed the member countries to grant such compulsory licence in order to make medicine cheaply available to the public.&lt;br /&gt;&lt;br /&gt;Declining to interfere with the order of compulsory licence, the Board said, &amp;ldquo;We are not inclined to interfere with the order of Controller General in the interest of the public. The invention must be available to the public at reasonable and affordable price if not compulsory licence is given.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;&amp;ldquo;We must bear in the mind of public interest but neither the investor nor the compulsory licence applicant. Patents are granted to benefit the inventions to the public.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;As per the licence conditions imposed by Controller, Natco had to pay a six per cent royalty to Bayer from the sales of generic drug Nexavar. Modifying this, the IPAB directed Natco to pay seven percent royalty. The IPAB also imposed Rs.50,000 cost on Natco for some &amp;ldquo;misinformation&amp;rdquo; in its affidavit.&lt;br /&gt;&lt;br /&gt;Bayer obtained a patent in India in 2008 for Nexavar which cost Rs. 2.8 lakh for a pack of 120 tablets, equivalent to a month&amp;rsquo;s dosage. On March 9, last year, the Controller of Patents, Mumbai, granted the first-ever compulsory licence to Natco to make &amp;lsquo;sorofenib tosylate&amp;rsquo;, a generic version of Bayer&amp;rsquo;s high-priced anti-cancer drug Nexavar. Natco was told to sell the pack at Rs. 8,800.&lt;br /&gt;&lt;br /&gt;Bayer appealed against the Controller&amp;rsquo;s order before the IPAB. Among other reasons, it contended that Cipla had started selling its generic version at a lower price, rendering the compulsory licence unnecessary as the drug was available at a reasonable price.&lt;br /&gt;&lt;br /&gt;Pronouncing the order on Monday, Justice Prabha Sridevan dealt elaborately with the appeal.&lt;br /&gt;&lt;br /&gt;Upholding the compulsory licence, the IPAB pointed out that even after obtaining patent, Bayer had not made the drug available on a large scale and at an affordable price within the stipulated time.&lt;br /&gt;&lt;br /&gt;Going into various submissions and affidavits filed by Bayer, the Board also came to conclusion that its pricing of Rs.2.8 lakh was not affordable.&lt;br /&gt;&lt;/div&gt;&lt;div align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div align=&quot;justify&quot;&gt;&lt;em&gt;Reuters reports:&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;In a separate case, Bayer has accused another Indian drugmaker, Cipla, of infringing its patent on Nexavar.&lt;br /&gt;&lt;br /&gt;Cipla had launched its generic version of Nexavar before Natco won the compulsory licence. Cipla undercut Natco&amp;rsquo;s price in May last year and now sells the drug at Rs.6,840 for a month&amp;rsquo;s dose.&lt;br /&gt;&lt;br /&gt;Among other setbacks for Western drug companies, India has revoked patents granted to Pfizer Inc&amp;rsquo;s cancer drug Sutent, Roche Holding AG&amp;rsquo;s hepatitis C drug Pegasys and Merck &amp;amp; Co&amp;rsquo;s asthma treatment aerosol suspension formulation. Another case involving drug patents is now in front of the Supreme Court, with Novartis battling against an earlier decision refusing it a patent on cancer drug Glivec. &lt;br /&gt;&lt;/div&gt;&#039;,
	&#039;lang&#039; =&gt; &#039;English&#039;,
	&#039;SITE_URL&#039; =&gt; &#039;https://im4change.in/&#039;,
	&#039;site_title&#039; =&gt; &#039;im4change&#039;,
	&#039;adminprix&#039; =&gt; &#039;admin&#039;
]
$article_current = object(App\Model\Entity\Article) {

	&#039;id&#039; =&gt; (int) 19606,
	&#039;title&#039; =&gt; &#039;Natco Pharma wins cancer drug case-R Sivaraman&#039;,
	&#039;subheading&#039; =&gt; &#039;&#039;,
	&#039;description&#039; =&gt; &#039;&lt;div align=&quot;justify&quot;&gt;
-The Hindu&lt;br /&gt;
&lt;br /&gt;
&lt;em&gt;Bayer&#039;s plea dismissed by the Intellectual Property Appellate Board&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a patented cancer drug of multinational pharma major Bayer Corporation. The order will pave the way for reduction in the prices of costly life saving drugs.&lt;br /&gt;
&lt;br /&gt;
Disposing an appeal filed by Bayer Corporation, the Board comprising its Chairman Justice Prabha Sridevan and member D.P.S. Parmar held that various international conventions and Indian laws allowed the member countries to grant such compulsory licence in order to make medicine cheaply available to the public.&lt;br /&gt;
&lt;br /&gt;
Declining to interfere with the order of compulsory licence, the Board said, &amp;ldquo;We are not inclined to interfere with the order of Controller General in the interest of the public. The invention must be available to the public at reasonable and affordable price if not compulsory licence is given.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
&amp;ldquo;We must bear in the mind of public interest but neither the investor nor the compulsory licence applicant. Patents are granted to benefit the inventions to the public.&amp;rdquo;&lt;br /&gt;
&lt;br /&gt;
As per the licence conditions imposed by Controller, Natco had to pay a six per cent royalty to Bayer from the sales of generic drug Nexavar. Modifying this, the IPAB directed Natco to pay seven percent royalty. The IPAB also imposed Rs.50,000 cost on Natco for some &amp;ldquo;misinformation&amp;rdquo; in its affidavit.&lt;br /&gt;
&lt;br /&gt;
Bayer obtained a patent in India in 2008 for Nexavar which cost Rs. 2.8 lakh for a pack of 120 tablets, equivalent to a month&amp;rsquo;s dosage. On March 9, last year, the Controller of Patents, Mumbai, granted the first-ever compulsory licence to Natco to make &amp;lsquo;sorofenib tosylate&amp;rsquo;, a generic version of Bayer&amp;rsquo;s high-priced anti-cancer drug Nexavar. Natco was told to sell the pack at Rs. 8,800.&lt;br /&gt;
&lt;br /&gt;
Bayer appealed against the Controller&amp;rsquo;s order before the IPAB. Among other reasons, it contended that Cipla had started selling its generic version at a lower price, rendering the compulsory licence unnecessary as the drug was available at a reasonable price.&lt;br /&gt;
&lt;br /&gt;
Pronouncing the order on Monday, Justice Prabha Sridevan dealt elaborately with the appeal.&lt;br /&gt;
&lt;br /&gt;
Upholding the compulsory licence, the IPAB pointed out that even after obtaining patent, Bayer had not made the drug available on a large scale and at an affordable price within the stipulated time.&lt;br /&gt;
&lt;br /&gt;
Going into various submissions and affidavits filed by Bayer, the Board also came to conclusion that its pricing of Rs.2.8 lakh was not affordable.&lt;br /&gt;
&lt;/div&gt;
&lt;div align=&quot;justify&quot;&gt;
&amp;nbsp;
&lt;/div&gt;
&lt;div align=&quot;justify&quot;&gt;
&lt;em&gt;Reuters reports:&lt;br /&gt;
&lt;/em&gt;&lt;br /&gt;
In a separate case, Bayer has accused another Indian drugmaker, Cipla, of infringing its patent on Nexavar.&lt;br /&gt;
&lt;br /&gt;
Cipla had launched its generic version of Nexavar before Natco won the compulsory licence. Cipla undercut Natco&amp;rsquo;s price in May last year and now sells the drug at Rs.6,840 for a month&amp;rsquo;s dose.&lt;br /&gt;
&lt;br /&gt;
Among other setbacks for Western drug companies, India has revoked patents granted to Pfizer Inc&amp;rsquo;s cancer drug Sutent, Roche Holding AG&amp;rsquo;s hepatitis C drug Pegasys and Merck &amp;amp; Co&amp;rsquo;s asthma treatment aerosol suspension formulation. Another case involving drug patents is now in front of the Supreme Court, with Novartis battling against an earlier decision refusing it a patent on cancer drug Glivec. &lt;br /&gt;
&lt;/div&gt;&#039;,
	&#039;credit_writer&#039; =&gt; &#039;The Hindu, 4 March, 2013, http://www.thehindu.com/business/companies/natco-pharma-wins-cancer-drug-case/article4475762.ece&#039;,
	&#039;article_img&#039; =&gt; &#039;&#039;,
	&#039;article_img_thumb&#039; =&gt; &#039;&#039;,
	&#039;status&#039; =&gt; (int) 1,
	&#039;show_on_home&#039; =&gt; (int) 1,
	&#039;lang&#039; =&gt; &#039;EN&#039;,
	&#039;category_id&#039; =&gt; (int) 16,
	&#039;tag_keyword&#039; =&gt; &#039;&#039;,
	&#039;seo_url&#039; =&gt; &#039;natco-pharma-wins-cancer-drug-case-r-sivaraman-19744&#039;,
	&#039;meta_title&#039; =&gt; null,
	&#039;meta_keywords&#039; =&gt; null,
	&#039;meta_description&#039; =&gt; null,
	&#039;noindex&#039; =&gt; (int) 0,
	&#039;publish_date&#039; =&gt; object(Cake\I18n\FrozenDate) {},
	&#039;most_visit_section_id&#039; =&gt; null,
	&#039;article_big_img&#039; =&gt; null,
	&#039;liveid&#039; =&gt; (int) 19744,
	&#039;created&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;modified&#039; =&gt; object(Cake\I18n\FrozenTime) {},
	&#039;edate&#039; =&gt; &#039;&#039;,
	&#039;tags&#039; =&gt; [
		(int) 0 =&gt; object(Cake\ORM\Entity) {},
		(int) 1 =&gt; object(Cake\ORM\Entity) {},
		(int) 2 =&gt; object(Cake\ORM\Entity) {},
		(int) 3 =&gt; object(Cake\ORM\Entity) {}
	],
	&#039;category&#039; =&gt; object(App\Model\Entity\Category) {},
	&#039;[new]&#039; =&gt; false,
	&#039;[accessible]&#039; =&gt; [
		&#039;*&#039; =&gt; true,
		&#039;id&#039; =&gt; false
	],
	&#039;[dirty]&#039; =&gt; [],
	&#039;[original]&#039; =&gt; [],
	&#039;[virtual]&#039; =&gt; [],
	&#039;[hasErrors]&#039; =&gt; false,
	&#039;[errors]&#039; =&gt; [],
	&#039;[invalid]&#039; =&gt; [],
	&#039;[repository]&#039; =&gt; &#039;Articles&#039;

}
$articleid = (int) 19606
$metaTitle = &#039;LATEST NEWS UPDATES | Natco Pharma wins cancer drug case-R Sivaraman&#039;
$metaKeywords = &#039;medicines,patents,Cancer,Health&#039;
$metaDesc = &#039;
-The Hindu

Bayer&#039;s plea dismissed by the Intellectual Property Appellate Board

The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a...&#039;
$disp = &#039;&lt;div align=&quot;justify&quot;&gt;-The Hindu&lt;br /&gt;&lt;br /&gt;&lt;em&gt;Bayer&#039;s plea dismissed by the Intellectual Property Appellate Board&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a patented cancer drug of multinational pharma major Bayer Corporation. The order will pave the way for reduction in the prices of costly life saving drugs.&lt;br /&gt;&lt;br /&gt;Disposing an appeal filed by Bayer Corporation, the Board comprising its Chairman Justice Prabha Sridevan and member D.P.S. Parmar held that various international conventions and Indian laws allowed the member countries to grant such compulsory licence in order to make medicine cheaply available to the public.&lt;br /&gt;&lt;br /&gt;Declining to interfere with the order of compulsory licence, the Board said, &amp;ldquo;We are not inclined to interfere with the order of Controller General in the interest of the public. The invention must be available to the public at reasonable and affordable price if not compulsory licence is given.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;&amp;ldquo;We must bear in the mind of public interest but neither the investor nor the compulsory licence applicant. Patents are granted to benefit the inventions to the public.&amp;rdquo;&lt;br /&gt;&lt;br /&gt;As per the licence conditions imposed by Controller, Natco had to pay a six per cent royalty to Bayer from the sales of generic drug Nexavar. Modifying this, the IPAB directed Natco to pay seven percent royalty. The IPAB also imposed Rs.50,000 cost on Natco for some &amp;ldquo;misinformation&amp;rdquo; in its affidavit.&lt;br /&gt;&lt;br /&gt;Bayer obtained a patent in India in 2008 for Nexavar which cost Rs. 2.8 lakh for a pack of 120 tablets, equivalent to a month&amp;rsquo;s dosage. On March 9, last year, the Controller of Patents, Mumbai, granted the first-ever compulsory licence to Natco to make &amp;lsquo;sorofenib tosylate&amp;rsquo;, a generic version of Bayer&amp;rsquo;s high-priced anti-cancer drug Nexavar. Natco was told to sell the pack at Rs. 8,800.&lt;br /&gt;&lt;br /&gt;Bayer appealed against the Controller&amp;rsquo;s order before the IPAB. Among other reasons, it contended that Cipla had started selling its generic version at a lower price, rendering the compulsory licence unnecessary as the drug was available at a reasonable price.&lt;br /&gt;&lt;br /&gt;Pronouncing the order on Monday, Justice Prabha Sridevan dealt elaborately with the appeal.&lt;br /&gt;&lt;br /&gt;Upholding the compulsory licence, the IPAB pointed out that even after obtaining patent, Bayer had not made the drug available on a large scale and at an affordable price within the stipulated time.&lt;br /&gt;&lt;br /&gt;Going into various submissions and affidavits filed by Bayer, the Board also came to conclusion that its pricing of Rs.2.8 lakh was not affordable.&lt;br /&gt;&lt;/div&gt;&lt;div align=&quot;justify&quot;&gt;&amp;nbsp;&lt;/div&gt;&lt;div align=&quot;justify&quot;&gt;&lt;em&gt;Reuters reports:&lt;br /&gt;&lt;/em&gt;&lt;br /&gt;In a separate case, Bayer has accused another Indian drugmaker, Cipla, of infringing its patent on Nexavar.&lt;br /&gt;&lt;br /&gt;Cipla had launched its generic version of Nexavar before Natco won the compulsory licence. Cipla undercut Natco&amp;rsquo;s price in May last year and now sells the drug at Rs.6,840 for a month&amp;rsquo;s dose.&lt;br /&gt;&lt;br /&gt;Among other setbacks for Western drug companies, India has revoked patents granted to Pfizer Inc&amp;rsquo;s cancer drug Sutent, Roche Holding AG&amp;rsquo;s hepatitis C drug Pegasys and Merck &amp;amp; Co&amp;rsquo;s asthma treatment aerosol suspension formulation. Another case involving drug patents is now in front of the Supreme Court, with Novartis battling against an earlier decision refusing it a patent on cancer drug Glivec. &lt;br /&gt;&lt;/div&gt;&#039;
$lang = &#039;English&#039;
$SITE_URL = &#039;https://im4change.in/&#039;
$site_title = &#039;im4change&#039;
$adminprix = &#039;admin&#039;</pre><pre class="stack-trace">include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51</pre></div></pre>latest-news-updates/natco-pharma-wins-cancer-drug-case-r-sivaraman-19744.html"/>
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
    <link href="https://im4change.in/css/control.css" rel="stylesheet" type="text/css"
          media="all"/>
    <title>LATEST NEWS UPDATES | Natco Pharma wins cancer drug case-R Sivaraman | Im4change.org</title>
    <meta name="description" content="
-The Hindu

Bayer's plea dismissed by the Intellectual Property Appellate Board

The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a..."/>
    <script src="https://im4change.in/js/jquery-1.10.2.js"></script>
    <script type="text/javascript" src="https://im4change.in/js/jquery-migrate.min.js"></script>
    <script language="javascript" type="text/javascript">

        $(document).ready(function () {
            var img = $("img")[0]; // Get my img elem
            var pic_real_width, pic_real_height;
            $("<img/>") // Make in memory copy of image to avoid css issues
                .attr("src", $(img).attr("src"))
                .load(function () {
                    pic_real_width = this.width;   // Note: $(this).width() will not
                    pic_real_height = this.height; // work for in memory images.
                });
        });
    </script>
    <style type="text/css">
        @media screen {
            div.divFooter {
                display: block;
            }
        }

        @media print {
            .printbutton {
                display: none !important;
            }
        }
    </style>
</head>
<body>
<table cellpadding="0" cellspacing="0" border="0" width="98%" align="center">
    <tr>
        <td class="top_bg">
            <div class="divFooter">
                <img src="https://im4change.in/images/logo1.jpg" height="59" border="0"
                     alt="Resource centre on India's rural distress" style="padding-top:14px;"/>
            </div>

        </td>
    </tr>
    <tr>
        <td id="topspace">&nbsp;</td>
    </tr>

    <tr id="topspace">
        <td>&nbsp;</td>
    </tr>
    <tr>
        <td height="50" style="border-bottom:1px solid #000; padding-top:10px;" class="printbutton">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>

    <tr>
        <td width="100%">
            <h1 class="news_headlines" style="font-style:normal">
                <strong>Natco Pharma wins cancer drug case-R Sivaraman</strong></h1>
        </td>
    </tr>
    <tr>
        <td width="100%" style="font-family:Arial, 'Segoe Script', 'Segoe UI', sans-serif, serif"><font size="3">
                <div align="justify">-The Hindu<br /><br /><em>Bayer's plea dismissed by the Intellectual Property Appellate Board<br /></em><br />The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a patented cancer drug of multinational pharma major Bayer Corporation. The order will pave the way for reduction in the prices of costly life saving drugs.<br /><br />Disposing an appeal filed by Bayer Corporation, the Board comprising its Chairman Justice Prabha Sridevan and member D.P.S. Parmar held that various international conventions and Indian laws allowed the member countries to grant such compulsory licence in order to make medicine cheaply available to the public.<br /><br />Declining to interfere with the order of compulsory licence, the Board said, &ldquo;We are not inclined to interfere with the order of Controller General in the interest of the public. The invention must be available to the public at reasonable and affordable price if not compulsory licence is given.&rdquo;<br /><br />&ldquo;We must bear in the mind of public interest but neither the investor nor the compulsory licence applicant. Patents are granted to benefit the inventions to the public.&rdquo;<br /><br />As per the licence conditions imposed by Controller, Natco had to pay a six per cent royalty to Bayer from the sales of generic drug Nexavar. Modifying this, the IPAB directed Natco to pay seven percent royalty. The IPAB also imposed Rs.50,000 cost on Natco for some &ldquo;misinformation&rdquo; in its affidavit.<br /><br />Bayer obtained a patent in India in 2008 for Nexavar which cost Rs. 2.8 lakh for a pack of 120 tablets, equivalent to a month&rsquo;s dosage. On March 9, last year, the Controller of Patents, Mumbai, granted the first-ever compulsory licence to Natco to make &lsquo;sorofenib tosylate&rsquo;, a generic version of Bayer&rsquo;s high-priced anti-cancer drug Nexavar. Natco was told to sell the pack at Rs. 8,800.<br /><br />Bayer appealed against the Controller&rsquo;s order before the IPAB. Among other reasons, it contended that Cipla had started selling its generic version at a lower price, rendering the compulsory licence unnecessary as the drug was available at a reasonable price.<br /><br />Pronouncing the order on Monday, Justice Prabha Sridevan dealt elaborately with the appeal.<br /><br />Upholding the compulsory licence, the IPAB pointed out that even after obtaining patent, Bayer had not made the drug available on a large scale and at an affordable price within the stipulated time.<br /><br />Going into various submissions and affidavits filed by Bayer, the Board also came to conclusion that its pricing of Rs.2.8 lakh was not affordable.<br /></div><div align="justify">&nbsp;</div><div align="justify"><em>Reuters reports:<br /></em><br />In a separate case, Bayer has accused another Indian drugmaker, Cipla, of infringing its patent on Nexavar.<br /><br />Cipla had launched its generic version of Nexavar before Natco won the compulsory licence. Cipla undercut Natco&rsquo;s price in May last year and now sells the drug at Rs.6,840 for a month&rsquo;s dose.<br /><br />Among other setbacks for Western drug companies, India has revoked patents granted to Pfizer Inc&rsquo;s cancer drug Sutent, Roche Holding AG&rsquo;s hepatitis C drug Pegasys and Merck &amp; Co&rsquo;s asthma treatment aerosol suspension formulation. Another case involving drug patents is now in front of the Supreme Court, with Novartis battling against an earlier decision refusing it a patent on cancer drug Glivec. <br /></div>               </font>
        </td>
    </tr>
    <tr>
        <td>&nbsp;</td>
    </tr>

    <tr>
        <td height="50" style="border-top:1px solid #000; border-bottom:1px solid #000;padding-top:10px;">
            <form><input type="button" value=" Print this page "
                         onclick="window.print();return false;"/></form>
        </td>
    </tr>
</table></body>
</html>'

}
$cookies = []
$values = [
	(int) 0 => 'text/html; charset=UTF-8'
]
$name = 'Content-Type'
$first = true
$value = 'text/html; charset=UTF-8'
header - [internal], line ??
Cake\Http\ResponseEmitter::emitHeaders() - CORE/src/Http/ResponseEmitter.php, line 181
Cake\Http\ResponseEmitter::emit() - CORE/src/Http/ResponseEmitter.php, line 55
Cake\Http\Server::emit() - CORE/src/Http/Server.php, line 141
[main] - ROOT/webroot/index.php, line 39

<head>

    <link rel="canonical" href="<?php echo Configure::read('SITE_URL'); ?><?php echo $urlPrefix;?><?php echo $article_current->category->slug; ?>/<?php echo $article_current->seo_url; ?>.html"/>

    <meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>

$viewFile = '/home/brlfuser/public_html/src/Template/Layout/printlayout.ctp'
$dataForView = [
	'article_current' => object(App\Model\Entity\Article) {

		'id' => (int) 19606,
		'title' => 'Natco Pharma wins cancer drug case-R Sivaraman',
		'subheading' => '',
		'description' => '<div align="justify">
-The Hindu<br />
<br />
<em>Bayer's plea dismissed by the Intellectual Property Appellate Board<br />
</em><br />
The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a patented cancer drug of multinational pharma major Bayer Corporation. The order will pave the way for reduction in the prices of costly life saving drugs.<br />
<br />
Disposing an appeal filed by Bayer Corporation, the Board comprising its Chairman Justice Prabha Sridevan and member D.P.S. Parmar held that various international conventions and Indian laws allowed the member countries to grant such compulsory licence in order to make medicine cheaply available to the public.<br />
<br />
Declining to interfere with the order of compulsory licence, the Board said, &ldquo;We are not inclined to interfere with the order of Controller General in the interest of the public. The invention must be available to the public at reasonable and affordable price if not compulsory licence is given.&rdquo;<br />
<br />
&ldquo;We must bear in the mind of public interest but neither the investor nor the compulsory licence applicant. Patents are granted to benefit the inventions to the public.&rdquo;<br />
<br />
As per the licence conditions imposed by Controller, Natco had to pay a six per cent royalty to Bayer from the sales of generic drug Nexavar. Modifying this, the IPAB directed Natco to pay seven percent royalty. The IPAB also imposed Rs.50,000 cost on Natco for some &ldquo;misinformation&rdquo; in its affidavit.<br />
<br />
Bayer obtained a patent in India in 2008 for Nexavar which cost Rs. 2.8 lakh for a pack of 120 tablets, equivalent to a month&rsquo;s dosage. On March 9, last year, the Controller of Patents, Mumbai, granted the first-ever compulsory licence to Natco to make &lsquo;sorofenib tosylate&rsquo;, a generic version of Bayer&rsquo;s high-priced anti-cancer drug Nexavar. Natco was told to sell the pack at Rs. 8,800.<br />
<br />
Bayer appealed against the Controller&rsquo;s order before the IPAB. Among other reasons, it contended that Cipla had started selling its generic version at a lower price, rendering the compulsory licence unnecessary as the drug was available at a reasonable price.<br />
<br />
Pronouncing the order on Monday, Justice Prabha Sridevan dealt elaborately with the appeal.<br />
<br />
Upholding the compulsory licence, the IPAB pointed out that even after obtaining patent, Bayer had not made the drug available on a large scale and at an affordable price within the stipulated time.<br />
<br />
Going into various submissions and affidavits filed by Bayer, the Board also came to conclusion that its pricing of Rs.2.8 lakh was not affordable.<br />
</div>
<div align="justify">
&nbsp;
</div>
<div align="justify">
<em>Reuters reports:<br />
</em><br />
In a separate case, Bayer has accused another Indian drugmaker, Cipla, of infringing its patent on Nexavar.<br />
<br />
Cipla had launched its generic version of Nexavar before Natco won the compulsory licence. Cipla undercut Natco&rsquo;s price in May last year and now sells the drug at Rs.6,840 for a month&rsquo;s dose.<br />
<br />
Among other setbacks for Western drug companies, India has revoked patents granted to Pfizer Inc&rsquo;s cancer drug Sutent, Roche Holding AG&rsquo;s hepatitis C drug Pegasys and Merck &amp; Co&rsquo;s asthma treatment aerosol suspension formulation. Another case involving drug patents is now in front of the Supreme Court, with Novartis battling against an earlier decision refusing it a patent on cancer drug Glivec. <br />
</div>',
		'credit_writer' => 'The Hindu, 4 March, 2013, http://www.thehindu.com/business/companies/natco-pharma-wins-cancer-drug-case/article4475762.ece',
		'article_img' => '',
		'article_img_thumb' => '',
		'status' => (int) 1,
		'show_on_home' => (int) 1,
		'lang' => 'EN',
		'category_id' => (int) 16,
		'tag_keyword' => '',
		'seo_url' => 'natco-pharma-wins-cancer-drug-case-r-sivaraman-19744',
		'meta_title' => null,
		'meta_keywords' => null,
		'meta_description' => null,
		'noindex' => (int) 0,
		'publish_date' => object(Cake\I18n\FrozenDate) {},
		'most_visit_section_id' => null,
		'article_big_img' => null,
		'liveid' => (int) 19744,
		'created' => object(Cake\I18n\FrozenTime) {},
		'modified' => object(Cake\I18n\FrozenTime) {},
		'edate' => '',
		'tags' => [
			[maximum depth reached]
		],
		'category' => object(App\Model\Entity\Category) {},
		'[new]' => false,
		'[accessible]' => [
			[maximum depth reached]
		],
		'[dirty]' => [[maximum depth reached]],
		'[original]' => [[maximum depth reached]],
		'[virtual]' => [[maximum depth reached]],
		'[hasErrors]' => false,
		'[errors]' => [[maximum depth reached]],
		'[invalid]' => [[maximum depth reached]],
		'[repository]' => 'Articles'
	
	},
	'articleid' => (int) 19606,
	'metaTitle' => 'LATEST NEWS UPDATES | Natco Pharma wins cancer drug case-R Sivaraman',
	'metaKeywords' => 'medicines,patents,Cancer,Health',
	'metaDesc' => '
-The Hindu

Bayer's plea dismissed by the Intellectual Property Appellate Board

The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a...',
	'disp' => '<div align="justify">-The Hindu<br /><br /><em>Bayer's plea dismissed by the Intellectual Property Appellate Board<br /></em><br />The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a patented cancer drug of multinational pharma major Bayer Corporation. The order will pave the way for reduction in the prices of costly life saving drugs.<br /><br />Disposing an appeal filed by Bayer Corporation, the Board comprising its Chairman Justice Prabha Sridevan and member D.P.S. Parmar held that various international conventions and Indian laws allowed the member countries to grant such compulsory licence in order to make medicine cheaply available to the public.<br /><br />Declining to interfere with the order of compulsory licence, the Board said, &ldquo;We are not inclined to interfere with the order of Controller General in the interest of the public. The invention must be available to the public at reasonable and affordable price if not compulsory licence is given.&rdquo;<br /><br />&ldquo;We must bear in the mind of public interest but neither the investor nor the compulsory licence applicant. Patents are granted to benefit the inventions to the public.&rdquo;<br /><br />As per the licence conditions imposed by Controller, Natco had to pay a six per cent royalty to Bayer from the sales of generic drug Nexavar. Modifying this, the IPAB directed Natco to pay seven percent royalty. The IPAB also imposed Rs.50,000 cost on Natco for some &ldquo;misinformation&rdquo; in its affidavit.<br /><br />Bayer obtained a patent in India in 2008 for Nexavar which cost Rs. 2.8 lakh for a pack of 120 tablets, equivalent to a month&rsquo;s dosage. On March 9, last year, the Controller of Patents, Mumbai, granted the first-ever compulsory licence to Natco to make &lsquo;sorofenib tosylate&rsquo;, a generic version of Bayer&rsquo;s high-priced anti-cancer drug Nexavar. Natco was told to sell the pack at Rs. 8,800.<br /><br />Bayer appealed against the Controller&rsquo;s order before the IPAB. Among other reasons, it contended that Cipla had started selling its generic version at a lower price, rendering the compulsory licence unnecessary as the drug was available at a reasonable price.<br /><br />Pronouncing the order on Monday, Justice Prabha Sridevan dealt elaborately with the appeal.<br /><br />Upholding the compulsory licence, the IPAB pointed out that even after obtaining patent, Bayer had not made the drug available on a large scale and at an affordable price within the stipulated time.<br /><br />Going into various submissions and affidavits filed by Bayer, the Board also came to conclusion that its pricing of Rs.2.8 lakh was not affordable.<br /></div><div align="justify">&nbsp;</div><div align="justify"><em>Reuters reports:<br /></em><br />In a separate case, Bayer has accused another Indian drugmaker, Cipla, of infringing its patent on Nexavar.<br /><br />Cipla had launched its generic version of Nexavar before Natco won the compulsory licence. Cipla undercut Natco&rsquo;s price in May last year and now sells the drug at Rs.6,840 for a month&rsquo;s dose.<br /><br />Among other setbacks for Western drug companies, India has revoked patents granted to Pfizer Inc&rsquo;s cancer drug Sutent, Roche Holding AG&rsquo;s hepatitis C drug Pegasys and Merck &amp; Co&rsquo;s asthma treatment aerosol suspension formulation. Another case involving drug patents is now in front of the Supreme Court, with Novartis battling against an earlier decision refusing it a patent on cancer drug Glivec. <br /></div>',
	'lang' => 'English',
	'SITE_URL' => 'https://im4change.in/',
	'site_title' => 'im4change',
	'adminprix' => 'admin'
]
$article_current = object(App\Model\Entity\Article) {

	'id' => (int) 19606,
	'title' => 'Natco Pharma wins cancer drug case-R Sivaraman',
	'subheading' => '',
	'description' => '<div align="justify">
-The Hindu<br />
<br />
<em>Bayer's plea dismissed by the Intellectual Property Appellate Board<br />
</em><br />
The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a patented cancer drug of multinational pharma major Bayer Corporation. The order will pave the way for reduction in the prices of costly life saving drugs.<br />
<br />
Disposing an appeal filed by Bayer Corporation, the Board comprising its Chairman Justice Prabha Sridevan and member D.P.S. Parmar held that various international conventions and Indian laws allowed the member countries to grant such compulsory licence in order to make medicine cheaply available to the public.<br />
<br />
Declining to interfere with the order of compulsory licence, the Board said, &ldquo;We are not inclined to interfere with the order of Controller General in the interest of the public. The invention must be available to the public at reasonable and affordable price if not compulsory licence is given.&rdquo;<br />
<br />
&ldquo;We must bear in the mind of public interest but neither the investor nor the compulsory licence applicant. Patents are granted to benefit the inventions to the public.&rdquo;<br />
<br />
As per the licence conditions imposed by Controller, Natco had to pay a six per cent royalty to Bayer from the sales of generic drug Nexavar. Modifying this, the IPAB directed Natco to pay seven percent royalty. The IPAB also imposed Rs.50,000 cost on Natco for some &ldquo;misinformation&rdquo; in its affidavit.<br />
<br />
Bayer obtained a patent in India in 2008 for Nexavar which cost Rs. 2.8 lakh for a pack of 120 tablets, equivalent to a month&rsquo;s dosage. On March 9, last year, the Controller of Patents, Mumbai, granted the first-ever compulsory licence to Natco to make &lsquo;sorofenib tosylate&rsquo;, a generic version of Bayer&rsquo;s high-priced anti-cancer drug Nexavar. Natco was told to sell the pack at Rs. 8,800.<br />
<br />
Bayer appealed against the Controller&rsquo;s order before the IPAB. Among other reasons, it contended that Cipla had started selling its generic version at a lower price, rendering the compulsory licence unnecessary as the drug was available at a reasonable price.<br />
<br />
Pronouncing the order on Monday, Justice Prabha Sridevan dealt elaborately with the appeal.<br />
<br />
Upholding the compulsory licence, the IPAB pointed out that even after obtaining patent, Bayer had not made the drug available on a large scale and at an affordable price within the stipulated time.<br />
<br />
Going into various submissions and affidavits filed by Bayer, the Board also came to conclusion that its pricing of Rs.2.8 lakh was not affordable.<br />
</div>
<div align="justify">
&nbsp;
</div>
<div align="justify">
<em>Reuters reports:<br />
</em><br />
In a separate case, Bayer has accused another Indian drugmaker, Cipla, of infringing its patent on Nexavar.<br />
<br />
Cipla had launched its generic version of Nexavar before Natco won the compulsory licence. Cipla undercut Natco&rsquo;s price in May last year and now sells the drug at Rs.6,840 for a month&rsquo;s dose.<br />
<br />
Among other setbacks for Western drug companies, India has revoked patents granted to Pfizer Inc&rsquo;s cancer drug Sutent, Roche Holding AG&rsquo;s hepatitis C drug Pegasys and Merck &amp; Co&rsquo;s asthma treatment aerosol suspension formulation. Another case involving drug patents is now in front of the Supreme Court, with Novartis battling against an earlier decision refusing it a patent on cancer drug Glivec. <br />
</div>',
	'credit_writer' => 'The Hindu, 4 March, 2013, http://www.thehindu.com/business/companies/natco-pharma-wins-cancer-drug-case/article4475762.ece',
	'article_img' => '',
	'article_img_thumb' => '',
	'status' => (int) 1,
	'show_on_home' => (int) 1,
	'lang' => 'EN',
	'category_id' => (int) 16,
	'tag_keyword' => '',
	'seo_url' => 'natco-pharma-wins-cancer-drug-case-r-sivaraman-19744',
	'meta_title' => null,
	'meta_keywords' => null,
	'meta_description' => null,
	'noindex' => (int) 0,
	'publish_date' => object(Cake\I18n\FrozenDate) {},
	'most_visit_section_id' => null,
	'article_big_img' => null,
	'liveid' => (int) 19744,
	'created' => object(Cake\I18n\FrozenTime) {},
	'modified' => object(Cake\I18n\FrozenTime) {},
	'edate' => '',
	'tags' => [
		(int) 0 => object(Cake\ORM\Entity) {},
		(int) 1 => object(Cake\ORM\Entity) {},
		(int) 2 => object(Cake\ORM\Entity) {},
		(int) 3 => object(Cake\ORM\Entity) {}
	],
	'category' => object(App\Model\Entity\Category) {},
	'[new]' => false,
	'[accessible]' => [
		'*' => true,
		'id' => false
	],
	'[dirty]' => [],
	'[original]' => [],
	'[virtual]' => [],
	'[hasErrors]' => false,
	'[errors]' => [],
	'[invalid]' => [],
	'[repository]' => 'Articles'

}
$articleid = (int) 19606
$metaTitle = 'LATEST NEWS UPDATES | Natco Pharma wins cancer drug case-R Sivaraman'
$metaKeywords = 'medicines,patents,Cancer,Health'
$metaDesc = '
-The Hindu

Bayer's plea dismissed by the Intellectual Property Appellate Board

The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a...'
$disp = '<div align="justify">-The Hindu<br /><br /><em>Bayer's plea dismissed by the Intellectual Property Appellate Board<br /></em><br />The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a patented cancer drug of multinational pharma major Bayer Corporation. The order will pave the way for reduction in the prices of costly life saving drugs.<br /><br />Disposing an appeal filed by Bayer Corporation, the Board comprising its Chairman Justice Prabha Sridevan and member D.P.S. Parmar held that various international conventions and Indian laws allowed the member countries to grant such compulsory licence in order to make medicine cheaply available to the public.<br /><br />Declining to interfere with the order of compulsory licence, the Board said, &ldquo;We are not inclined to interfere with the order of Controller General in the interest of the public. The invention must be available to the public at reasonable and affordable price if not compulsory licence is given.&rdquo;<br /><br />&ldquo;We must bear in the mind of public interest but neither the investor nor the compulsory licence applicant. Patents are granted to benefit the inventions to the public.&rdquo;<br /><br />As per the licence conditions imposed by Controller, Natco had to pay a six per cent royalty to Bayer from the sales of generic drug Nexavar. Modifying this, the IPAB directed Natco to pay seven percent royalty. The IPAB also imposed Rs.50,000 cost on Natco for some &ldquo;misinformation&rdquo; in its affidavit.<br /><br />Bayer obtained a patent in India in 2008 for Nexavar which cost Rs. 2.8 lakh for a pack of 120 tablets, equivalent to a month&rsquo;s dosage. On March 9, last year, the Controller of Patents, Mumbai, granted the first-ever compulsory licence to Natco to make &lsquo;sorofenib tosylate&rsquo;, a generic version of Bayer&rsquo;s high-priced anti-cancer drug Nexavar. Natco was told to sell the pack at Rs. 8,800.<br /><br />Bayer appealed against the Controller&rsquo;s order before the IPAB. Among other reasons, it contended that Cipla had started selling its generic version at a lower price, rendering the compulsory licence unnecessary as the drug was available at a reasonable price.<br /><br />Pronouncing the order on Monday, Justice Prabha Sridevan dealt elaborately with the appeal.<br /><br />Upholding the compulsory licence, the IPAB pointed out that even after obtaining patent, Bayer had not made the drug available on a large scale and at an affordable price within the stipulated time.<br /><br />Going into various submissions and affidavits filed by Bayer, the Board also came to conclusion that its pricing of Rs.2.8 lakh was not affordable.<br /></div><div align="justify">&nbsp;</div><div align="justify"><em>Reuters reports:<br /></em><br />In a separate case, Bayer has accused another Indian drugmaker, Cipla, of infringing its patent on Nexavar.<br /><br />Cipla had launched its generic version of Nexavar before Natco won the compulsory licence. Cipla undercut Natco&rsquo;s price in May last year and now sells the drug at Rs.6,840 for a month&rsquo;s dose.<br /><br />Among other setbacks for Western drug companies, India has revoked patents granted to Pfizer Inc&rsquo;s cancer drug Sutent, Roche Holding AG&rsquo;s hepatitis C drug Pegasys and Merck &amp; Co&rsquo;s asthma treatment aerosol suspension formulation. Another case involving drug patents is now in front of the Supreme Court, with Novartis battling against an earlier decision refusing it a patent on cancer drug Glivec. <br /></div>'
$lang = 'English'
$SITE_URL = 'https://im4change.in/'
$site_title = 'im4change'
$adminprix = 'admin'

include - APP/Template/Layout/printlayout.ctp, line 8
Cake\View\View::_evaluate() - CORE/src/View/View.php, line 1413
Cake\View\View::_render() - CORE/src/View/View.php, line 1374
Cake\View\View::renderLayout() - CORE/src/View/View.php, line 927
Cake\View\View::render() - CORE/src/View/View.php, line 885
Cake\Controller\Controller::render() - CORE/src/Controller/Controller.php, line 791
Cake\Http\ActionDispatcher::_invoke() - CORE/src/Http/ActionDispatcher.php, line 126
Cake\Http\ActionDispatcher::dispatch() - CORE/src/Http/ActionDispatcher.php, line 94
Cake\Http\BaseApplication::__invoke() - CORE/src/Http/BaseApplication.php, line 235
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\RoutingMiddleware::__invoke() - CORE/src/Routing/Middleware/RoutingMiddleware.php, line 162
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Routing\Middleware\AssetMiddleware::__invoke() - CORE/src/Routing/Middleware/AssetMiddleware.php, line 88
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Error\Middleware\ErrorHandlerMiddleware::__invoke() - CORE/src/Error/Middleware/ErrorHandlerMiddleware.php, line 96
Cake\Http\Runner::__invoke() - CORE/src/Http/Runner.php, line 65
Cake\Http\Runner::run() - CORE/src/Http/Runner.php, line 51

Natco Pharma wins cancer drug case-R Sivaraman

-The Hindu Bayer's plea dismissed by the Intellectual Property Appellate Board The Intellectual Property Appellate Board (IPAB) on Monday upheld the grant of compulsory licence (CL) to the Hyderabad-based Natco Pharma Limited, a generic drug maker, to produce and market Nexavar, a patented cancer drug of multinational pharma major Bayer Corporation. The order will pave the way for reduction in the prices of costly life saving drugs. Disposing an appeal filed by Bayer Corporation, the Board comprising its Chairman Justice Prabha Sridevan and member D.P.S. Parmar held that various international conventions and Indian laws allowed the member countries to grant such compulsory licence in order to make medicine cheaply available to the public. Declining to interfere with the order of compulsory licence, the Board said, “We are not inclined to interfere with the order of Controller General in the interest of the public. The invention must be available to the public at reasonable and affordable price if not compulsory licence is given.” “We must bear in the mind of public interest but neither the investor nor the compulsory licence applicant. Patents are granted to benefit the inventions to the public.” As per the licence conditions imposed by Controller, Natco had to pay a six per cent royalty to Bayer from the sales of generic drug Nexavar. Modifying this, the IPAB directed Natco to pay seven percent royalty. The IPAB also imposed Rs.50,000 cost on Natco for some “misinformation” in its affidavit. Bayer obtained a patent in India in 2008 for Nexavar which cost Rs. 2.8 lakh for a pack of 120 tablets, equivalent to a month’s dosage. On March 9, last year, the Controller of Patents, Mumbai, granted the first-ever compulsory licence to Natco to make ‘sorofenib tosylate’, a generic version of Bayer’s high-priced anti-cancer drug Nexavar. Natco was told to sell the pack at Rs. 8,800. Bayer appealed against the Controller’s order before the IPAB. Among other reasons, it contended that Cipla had started selling its generic version at a lower price, rendering the compulsory licence unnecessary as the drug was available at a reasonable price. Pronouncing the order on Monday, Justice Prabha Sridevan dealt elaborately with the appeal. Upholding the compulsory licence, the IPAB pointed out that even after obtaining patent, Bayer had not made the drug available on a large scale and at an affordable price within the stipulated time. Going into various submissions and affidavits filed by Bayer, the Board also came to conclusion that its pricing of Rs.2.8 lakh was not affordable.   Reuters reports: In a separate case, Bayer has accused another Indian drugmaker, Cipla, of infringing its patent on Nexavar. Cipla had launched its generic version of Nexavar before Natco won the compulsory licence. Cipla undercut Natco’s price in May last year and now sells the drug at Rs.6,840 for a month’s dose. Among other setbacks for Western drug companies, India has revoked patents granted to Pfizer Inc’s cancer drug Sutent, Roche Holding AG’s hepatitis C drug Pegasys and Merck & Co’s asthma treatment aerosol suspension formulation. Another case involving drug patents is now in front of the Supreme Court, with Novartis battling against an earlier decision refusing it a patent on cancer drug Glivec.